High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group

@article{Colombat2006HighdoseCW,
  title={High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group},
  author={Ph Colombat and A Lemevel and Philippe Bertrand and V Delwail and Petronella Rachieru and A BSTRACT. M. Brion and Christian Berthou and Jacques Olivier Bay and Roselyne Del{\'e}pine and Bernard Desablens and Sophie Camilleri-Br{\"o}et and Claude Linassier and Thierney Lamy},
  journal={Bone Marrow Transplantation},
  year={2006},
  volume={38},
  pages={417-420}
}
The optimum treatment of primary CNS lymphoma (PCNSL) is not yet determined. The objective of this study was to assess the safety and efficacy of initial methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) in patients with newly diagnosed PCNSL. Twenty-five patients received two courses of initial chemotherapy combining methotrexate, etoposide, carmustine and methylprednisolone, and one course of ifosfamide–cytarabine… CONTINUE READING